Pipeline
Proprietary platform technologies and product candidates.
Candidate
Tarctet
Indication
Preclinical
Clinical PoC
IND Study
  • (first-in-class)
    GC007F (anti-CD19)
    anti-CD19
    r/r B-ALL
    ALL
    Adult acute lymphoblastic leukemia (ALL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Leukemia may affect red blood cells, white blood cells, and platelets.
  • DUAL CAR
    GC022*
    anti-CD19-CD22
    r/r B-ALL
    ALL
    Adult acute lymphoblastic leukemia (ALL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Leukemia may affect red blood cells, white blood cells, and platelets.
    GC012*
    anti-BCMA-Ag X
    advanced MM
    MM
    Myeloma begins when a plasma cell becomes abnormal. The abnormal cell divides to make copies of itself. These abnormal plasma cells are called myeloma cells. In time, myeloma cells collect in the bone marrow. They may damage the solid part of the bone. When myeloma cells collect in several of your bones, the disease is called "multiple myeloma." This disease may also harm other tissues and organs, such as the kidneys.Myeloma cells make antibodies called M proteins and other proteins. These proteins can collect in the blood, urine, and organs.
  • TruUCAR
    (first-in-class)
    GC027*
    anti-Ag X
    Acute leukemia
  • Enhanced CAR
    GC008t
    anti-meso
    Meso+ malignancies
*Considering to convert to FasT CAR processing.